ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

被引：34

作者：

Huang, Zhao-Hui ^{[1
,2
]}

Hua, Dong ^{[1
]}

Du, Xiang ^{[2
]}

Li, Li-Hua ^{[1
]}

Mao, Yong ^{[1
]}

Liu, Zhi-Hui ^{[1
]}

Song, Ming-Xu ^{[1
]}

Zhou, Xi-Ke ^{[1
]}

机构：

[1] Suzhou Univ, Affiliated Hosp 4, Wuxi Oncol Inst, Wuxi 214026, Jiangsu Prov, Peoples R China

[2] Fudan Univ, Canc Hosp, Dept Pathol, Shanghai 200032, Peoples R China

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2008年 / 14卷 / 41期

关键词：

Gastric cancer; Adjuvant chemotherapy; Excision repair cross complementing group 1; Gene polymorphism;

D O I：

10.3748/wjg.14.6401

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AIM: To determine the influence of excision repair cross complementing group 1 (ERCC1) codon 118 polymorphism and mRNA level on the clinical outcome of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. METHODS: Eighty-nine gastric cancer patients treated with oxalipatin-based adjuvant chemotherapy were included in this study. ERCC1 codon 118 C/T polymorphism was tested by polymerase chain reaction-ligation detection reaction (PCR-LDR) method in peripheral blood lymphocytes of those patients; and the intratumoral ERCC1 mRNA expression was measured using reverse transcription PCR in 62 patients whose tumor tissue specimens were available. RESULTS: No significant relationship was found between ERCC1 codon 118 polymorphism and ERCC1 mRNA level. The median relapse-free and overall survival period was 20.1 mo and 28.4 mo, respectively. The relapse-free and overall survivals in patients with low levels of ERCC1 mRNA were significantly longer than those in patients with high levels (P < 0.05), while there was no significant association found between ERCC1 118 genotypes and the disease prognosis. Multivariate analysis also showed that ERCC1 mRNA level was a potential predictor for relapse and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy (P < 0.05). CONCLUSION: ERCC1 codon 118 polymorphism has no significant impact on ERCC1 mRNA expression, and the intratumoral ERCC1 mRNA level but not codon 118 polymorphism may be a useful predictive parameter for the relapse and survival of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy. (C) 2008 The WJG Press. All -rights reserved.

引用

页码：6401 / 6407

页数：7

共 36 条

[21]

Park David J, 2003, Clin Adv Hematol Oncol, V1, P162

[22]

PARK DJ, 2002, AM ASS CANC RES 93 A

[23] Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy [J].

Ruzzo, A ;

Graziano, F ;

Kawakami, K ;

Watanabe, G ;

Santini, D ;

Catalano, V ;

Bisonni, R ;

Canestrari, E ;

Ficarelli, R ;

Menichetti, ET ;

Mari, D ;

Testa, E ;

Silva, R ;

Vincenzi, B ;

Giordani, P ;

Cascinu, S ;

Giustini, L ;

Tonini, G ;

Magnani, M .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) :1883-1891

[24] Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy [J].

Ruzzo, Annamaria ;

Graziano, Francesco ;

Loupakis, Fotios ;

Rulli, Eliana ;

Canestrari, Emanuele ;

Santini, Daniele ;

Catalano, Vincenzo ;

Ficarelli, Rita ;

Maltese, Paolo ;

Bisonni, Renato ;

Masi, Gianluca ;

Schiavon, Gaia ;

Giordani, Paolo ;

Giustini, Lucio ;

Falcone, Alfredo ;

Tonini, Giuseppe ;

Silva, Rosarita ;

Mattioli, Rodolfo ;

Floriani, Irene ;

Magnani, Mauro .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (10) :1247-1254

[25] Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy [J].

Ryu, JS ;

Hong, YC ;

Han, HS ;

Lee, JE ;

Kim, S ;

Parke, YM ;

Kim, YC ;

Hwang, TS .

LUNG CANCER, 2004, 44 (03) :311-316

[26] ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy [J].

Shirota, Y ;

Stoehlmacher, J ;

Brabender, J ;

Xiang, YP ;

Uetake, H ;

Danenberg, KD ;

Groshen, S ;

Tsao-Wei, DD ;

Danenberg, PV ;

Lenz, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (23) :4298-4304

[27] Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer [J].

Steffensen, K. D. ;

Waldstrom, M. ;

Jeppesen, U. ;

Brandslund, I. ;

Jakobsen, A. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (04) :702-710

[28] A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer [J].

Stoehlmacher, J ;

Park, DJ ;

Zhang, W ;

Yang, D ;

Groshen, S ;

Zahedy, S ;

Lenz, HJ .

BRITISH JOURNAL OF CANCER, 2004, 91 (02) :344-354

[29] Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients [J].

Suk, R ;

Gurubhagavatula, S ;

Park, S ;

Zhou, W ;

Su, L ;

Lynch, TJ ;

Wain, JC ;

Neuberg, D ;

Liu, G ;

Christiani, DC .

CLINICAL CANCER RESEARCH, 2005, 11 (04) :1534-1538

[30] Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin -: Treated advanced non-small cell lung cancer patients [J].

Tibaldi, Carmelo ;

Giovannetti, Elisa ;

Vasile, Enrico ;

Mey, Valentina ;

Laan, Adrie C. ;

Nannizzi, Sara ;

Di Marsico, Roberta ;

Antonuzzo, Andrea ;

Orlandini, Cinzia ;

Ricciardi, Simona ;

Del Tacca, Mario ;

Peters, Godefridus J. ;

Falcone, Alfredo ;

Danesi, Romano .

CLINICAL CANCER RESEARCH, 2008, 14 (06) :1797-1803

← 1 2 3 4 →